Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Biogen to $305 from $310 and keeps a Buy rating on the shares. The firm believes Leqembi remains a solid long-term driver especially if maintenance dosing and the subcutaneous formulation are approvedand as a result the firm continues to believe the stock could work well for patient investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- QQQ ETF Update, 2/19/2024
- Sage Therapeutics price target raised to $25 from $23 at Oppenheimer
- Biogen price target lowered to $230 from $255 at Barclays
- Biogen price target lowered to $275 from $304 at Scotiabank
- Biogen price target lowered to $290 from $295 at Oppenheimer
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue